A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Routine Clinical Care in Patients With Epilepsy
Latest Information Update: 19 Oct 2021
At a glance
- Drugs Perampanel (Primary)
- Indications Absence epilepsy; Complex partial epilepsy; Epilepsy; Generalised epilepsy; Myoclonic epilepsies; Partial epilepsies; Tonic-clonic epilepsy
- Focus Therapeutic Use
- Sponsors Eisai Inc
Most Recent Events
- 01 Sep 2021 Results assessing efficacy/safety of perampanel monotherapy in patients with epilepsy using data from clinical trial (study 342; n=89) and real-world use (studies 504; n=60 and 506; n=47), presented at the 34th International Epilepsy Congress.
- 22 Apr 2021 Results assessing efficacy/safety of perampanel monotherapy in patients with epilepsy using data from study 504, 506 and 342 presented at the 73rd Annual Meeting of the American Academy of Neurology
- 08 Dec 2020 Results assessing clinical evidence for perampanel monotherapy from following clinical studies: two retrospective non-interventional phase IV studies: NCT02736162 and NCT03208660; one open-label phase III study NCT03201900 presented at the 74th Annual Meeting of the American Epilepsy Society